126 related articles for article (PubMed ID: 10444318)
21. Antimicrobial susceptibility of Shigella flexneri and S. dysenteriae isolated from stool specimens of patients with bloody diarrhoea in Mwanza, Tanzania.
Temu MM; Kaatano GM; Miyaye ND; Buhalata SN; Shushu ML; Kishamawe C; Changalucha JM
Tanzan Health Res Bull; 2007 Sep; 9(3):186-9. PubMed ID: 18087897
[TBL] [Abstract][Full Text] [Related]
22. Activities of aqueous extracts of Mallotus oppositifolium on Shigella dysenteriae A1-induced diarrhoea in rats.
Kamgang R; Vidal Pouokam Kamgne E; Fonkoua MC; Penlap N Beng V; Biwolé Sida M
Clin Exp Pharmacol Physiol; 2006; 33(1-2):89-94. PubMed ID: 16445705
[TBL] [Abstract][Full Text] [Related]
23. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis.
Salam MA; Dhar U; Khan WA; Bennish ML
Lancet; 1998 Aug; 352(9127):522-7. PubMed ID: 9716056
[TBL] [Abstract][Full Text] [Related]
24. Shigella dysenteriae type 1 with reduced susceptibility to fluoroquinolones.
Sarkar K; Ghosh S; Niyogi SK; Bhattacharya SK
Lancet; 2003 Mar; 361(9359):785. PubMed ID: 12620764
[No Abstract] [Full Text] [Related]
25. The changing epidemiology of bacillary dysentery and characteristics of antimicrobial resistance of Shigella isolated in China from 2004-2014.
Chang Z; Zhang J; Ran L; Sun J; Liu F; Luo L; Zeng L; Wang L; Li Z; Yu H; Liao Q
BMC Infect Dis; 2016 Nov; 16(1):685. PubMed ID: 27863468
[TBL] [Abstract][Full Text] [Related]
26. Nalidixic acid-resistant Shigella dysenteriae type I in KwaZulu-Natal.
Karas JA; Pillay DG
S Afr Med J; 1996 Jan; 86(1):93. PubMed ID: 8685796
[No Abstract] [Full Text] [Related]
27. Increasing incidence of resistance to nalidixic acid in shigellas from humans in England and Wales: implications for therapy.
Cheasty T; Day M; Threlfall EJ
Clin Microbiol Infect; 2004 Nov; 10(11):1033-5. PubMed ID: 15522014
[TBL] [Abstract][Full Text] [Related]
28. [Pathogenic surveillance and related factors on bacillary dysentery in Beijing, 2008-2017].
Jia L; Lyu B; Tian Y; Zhang X; Liu ZC; Peng H; Li HJ; Zhen BJ; Wang XL; Huang Y; Qu M; Wang QY
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):165-169. PubMed ID: 30744266
[No Abstract] [Full Text] [Related]
29. Predictors of mortality in children hospitalized with dysentery in Harare, Zimbabwe.
Nathoo KJ; Porteous JE; Siziya S; Wellington M; Mason E
Cent Afr J Med; 1998 Nov; 44(11):272-6. PubMed ID: 10910572
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial resistance and serotypes of Shigella isolates in Kigali, Rwanda (1983 to 1993): increasing frequency of multiple resistance.
Bogaerts J; Verhaegen J; Munyabikali JP; Mukantabana B; Lemmens P; Vandeven J; Vandepitte J
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):165-71. PubMed ID: 9327243
[TBL] [Abstract][Full Text] [Related]
31. Nonserotypeable Shigella dysenteriae isolated from a Dutch patient returning from India.
Kuijper EJ; van Eeden A; de Wever B; van Ketel R; Dankert J
Eur J Clin Microbiol Infect Dis; 1997 Jul; 16(7):553-4. PubMed ID: 9272399
[No Abstract] [Full Text] [Related]
32. An epidemic of bacillary dysentery in western Rwanda 1981-1982.
Huppertz HI
Cent Afr J Med; 1986 Mar; 32(3):79-82. PubMed ID: 3533269
[TBL] [Abstract][Full Text] [Related]
33. Microbiological investigation of diarrhoea epidemics among Rwandan refugees in Zaire.
Islam MS; Siddique AK; Salam A; Akram K; Majumdar RN; Zaman K; Fronczak N; Laston S
Trans R Soc Trop Med Hyg; 1995; 89(5):506. PubMed ID: 8560524
[No Abstract] [Full Text] [Related]
34. Comparative efficacy of furazolidone and nalidixic acid in the empirical treatment of acute invasive diarrhea: randomized clinical trial.
Dutta P; Sett A; Sarkar A; Mitra U; Saha D; Manna B; Kundu B; Gupta A
Indian Pediatr; 1995 Jan; 32(1):13-9. PubMed ID: 8617528
[TBL] [Abstract][Full Text] [Related]
35. Unusual association of a plasmid with nalidixic acid resistance in an epidemic strain of Shigella dysenteriae type 1 from Asia.
Ashraf MM; Ahmed ZU; Sack DA
Can J Microbiol; 1991 Jan; 37(1):59-63. PubMed ID: 2021898
[TBL] [Abstract][Full Text] [Related]
36. Antibiotics in the management of shigellosis in children: what role for the quinolones?
Fontaine O
Rev Infect Dis; 1989; 11 Suppl 5():S1145-50. PubMed ID: 2672246
[TBL] [Abstract][Full Text] [Related]
37. Nalidixic acid is still the drug of choice for shigellosis in Pakistan.
Mahmood A
J Pak Med Assoc; 2001 Feb; 51(2):101. PubMed ID: 11321869
[No Abstract] [Full Text] [Related]
38. Emergence of quinolone-resistant Shigella dysenteriae type 1 in Canada.
Can Commun Dis Rep; 2005 Oct; 31(19):193-7. PubMed ID: 16200675
[No Abstract] [Full Text] [Related]
39. Multiresistant Shigella infections in Bangladesh.
Bennish M; Eusof A; Kay B; Wierzba T
Lancet; 1985 Aug; 2(8452):441. PubMed ID: 2863461
[No Abstract] [Full Text] [Related]
40. Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from 1998 to 2009.
Gu B; Cao Y; Pan S; Zhuang L; Yu R; Peng Z; Qian H; Wei Y; Zhao L; Liu G; Tong M
Int J Antimicrob Agents; 2012 Jul; 40(1):9-17. PubMed ID: 22483324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
